FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004111276> ?p ?o ?g. }

• W2004111276 endingPage "A480" @default.
• W2004111276 startingPage "A479" @default.
• W2004111276 abstract "Upper limb spasticity (ULS) secondary to stroke has a considerable patient and caregiver burden, particularly with regards to pain, activities of daily living and mobility. Botulinum neurotoxin-A (BoNT-A) injections are effective in treating ULS. We aimed to calculate annual BoNT-A treatment cost of ULS on a per-patient basis, and the expected overall annual budget impact of BoNT-A treatment in Germany using static and dynamic market share scenarios. A budget impact model for BoNT-A use, adopting a German health care system perspective, was developed. Two market-share scenarios were modelled over 5 years. While the static scenario assumed current market shares (abobotulinumtoxinA, 36%; onabotulinumtoxinA, 26%; incobotulinumtoxinA, 38%) to remain constant over time, the dynamic scenario assumed market share of abobotulinumtoxinA to rise up to 76% across 5 years. Epidemiologic data inputs were sourced from the most recently published literature, unit costs for BoNT-As from the Lauertaxe (pharmacy purchase price [PPP] level), and market share assumptions from IMS Health (Market Sizing). Equivalence of the 3 BoNTAs in terms of efficacy and safety is assumed and therefore no differential use of medical services or other goods. Annual BoNT-A drug costs per ULS patient were 3 463€, 5 603€, and 5 410€, respectively, with prescribing patterns following SmPC recommendations for abobotulinumtoxinA, onabotulinumtoxinA, and incobotulinumtoxinA. The total drug costs were decreased by between 1 231 861€ (-4%) in year 2 and 5 133 684€ (-17%) in year 5 by shifting the market share to abobotulinumtoxinA. Sensitivity analyses showed that the number of patients treated with BoNT-As, time to re-injection, and dose per injection were the most influential parameters on budget impact, impacting both drug acquisition costs and physician visits. Increased use of abobotulinumtoxinA compared with incobotulinumtoxinA and onabotulinumtoxinA for ULS in Germany could potentially reduce the total cost of treatment." @default.
• W2004111276 created "2016-06-24" @default.
• W2004111276 creator A5011703237 @default.
• W2004111276 creator A5033354150 @default.
• W2004111276 creator A5050211095 @default.
• W2004111276 date "2014-11-01" @default.
• W2004111276 modified "2023-10-02" @default.
• W2004111276 title "Budget Impact Analysis Of Botulinum Toxin A Therapy For Upper Limb Spasticity In Germany" @default.
• W2004111276 doi "https://doi.org/10.1016/j.jval.2014.08.1386" @default.
• W2004111276 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27201392" @default.
• W2004111276 hasPublicationYear "2014" @default.
• W2004111276 type Work @default.
• W2004111276 sameAs 2004111276 @default.
• W2004111276 citedByCount "1" @default.
• W2004111276 countsByYear W20041112762023 @default.
• W2004111276 crossrefType "journal-article" @default.
• W2004111276 hasAuthorship W2004111276A5011703237 @default.
• W2004111276 hasAuthorship W2004111276A5033354150 @default.
• W2004111276 hasAuthorship W2004111276A5050211095 @default.
• W2004111276 hasBestOaLocation W20041112761 @default.
• W2004111276 hasConcept C144133560 @default.
• W2004111276 hasConcept C16051113 @default.
• W2004111276 hasConcept C162853370 @default.
• W2004111276 hasConcept C1862650 @default.
• W2004111276 hasConcept C71924100 @default.
• W2004111276 hasConcept C99508421 @default.
• W2004111276 hasConceptScore W2004111276C144133560 @default.
• W2004111276 hasConceptScore W2004111276C16051113 @default.
• W2004111276 hasConceptScore W2004111276C162853370 @default.
• W2004111276 hasConceptScore W2004111276C1862650 @default.
• W2004111276 hasConceptScore W2004111276C71924100 @default.
• W2004111276 hasConceptScore W2004111276C99508421 @default.
• W2004111276 hasIssue "7" @default.
• W2004111276 hasLocation W20041112761 @default.
• W2004111276 hasLocation W20041112762 @default.
• W2004111276 hasOpenAccess W2004111276 @default.
• W2004111276 hasPrimaryLocation W20041112761 @default.
• W2004111276 hasRelatedWork W1821496887 @default.
• W2004111276 hasRelatedWork W1968052731 @default.
• W2004111276 hasRelatedWork W2092185945 @default.
• W2004111276 hasRelatedWork W2103412063 @default.
• W2004111276 hasRelatedWork W2155717209 @default.
• W2004111276 hasRelatedWork W2560205657 @default.
• W2004111276 hasRelatedWork W2913230942 @default.
• W2004111276 hasRelatedWork W3189279688 @default.
• W2004111276 hasRelatedWork W4224285088 @default.
• W2004111276 hasRelatedWork W4310995375 @default.
• W2004111276 hasVolume "17" @default.
• W2004111276 isParatext "false" @default.
• W2004111276 isRetracted "false" @default.
• W2004111276 magId "2004111276" @default.
• W2004111276 workType "article" @default.